Hi hargo, thank you for the clarification regarding the cost savings over 3 years. I should have looked back at the original announcement.
Why announce the cost savings over 3 years? Does that mean that Imugene would have incurred T cell manufacturing costs of $A49 million over next 3 years without generating any sales income over the same period!
Maybe the "up to $6M USD in upfront and milestone-driven payments over three years" is the only revenue gain to Imugene.
Maybe "the strategic manufacturing and process development partnership will support
Imugene’s Azer-cel clinical study supply" is a guarantee of supply to Imugene at an agreed cost price.
hargo, I was aware of the Azer-cel 1 year payment in August.
Imugene acquired Azer-cel, so CHEAP in a roundabout way.
Regards.
Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-115
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $389.5M | |||
| Open | High | Low | Value | Volume |
| 5.3¢ | 5.4¢ | 5.1¢ | $717.6K | 13.61M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 1468251 | 5.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.4¢ | 457393 | 5 |
View Market Depth
| Last trade - 16.10pm 31/07/2024 (20 minute delay) ? |
| IMU (ASX) Chart |